Gilead Sciences
GILD
1,604 hedge funds and large institutions have $61.4B invested in Gilead Sciences in 2022 Q2 according to their latest regulatory filings, with 143 funds opening new positions, 689 increasing their positions, 578 reducing their positions, and 119 closing their positions.
46% more call options, than puts
Call options by funds: $1.14B | Put options by funds: $780M
33% more funds holding in top 10
Funds holding in top 10: 24 → 32 (+8)
20% more first-time investments, than exits
New positions opened: 143 | Existing positions closed: 119
19% more repeat investments, than reductions
Existing positions increased: 689 | Existing positions reduced: 578
4% more capital invested
Capital invested by funds: $59.1B → $61.4B (+$2.34B)
0% more funds holding
Funds holding: 1,601 → 1,604 (+3)
0.1% more ownership
Funds ownership: 79.28% → 79.38% (+0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$324M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$296M |
| 3 |
Morgan Stanley
New York
|
+$268M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$209M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$208M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$209M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$209M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$159M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$149M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$149M |
GILD Hedge Fund Activity: Q2 2022 in Review
1,604 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2022, worth a combined $61.4B — up 4% from $59.1B a quarter earlier.
Buyers outnumbered sellers: 143 funds opened new GILD positions and 119 closed out — a net gain of 24 holders — while 689 added to existing stakes and 578 trimmed.
The largest buyer was BlackRock, adding an estimated $324M. The largest seller was D.E. Shaw & Co, cutting an estimated $209M.
- 1,604 institutional investors held Gilead Sciences (GILD) as of Q2 2022, up from 1,601 in Q1 2022.
- Funds reported $61.4B of Gilead Sciences stock for Q2 2022, up 4% quarter-over-quarter.
- 143 funds opened new Gilead Sciences positions in Q2 2022 and 119 closed out, a net change of +24 holders.
- The largest Gilead Sciences buyer in Q2 2022 was BlackRock, an estimated $324M added.
- The largest Gilead Sciences seller in Q2 2022 was D.E. Shaw & Co, an estimated $209M sold.
Based on aggregated 13F filings for Q2 2022.